Cawachi Ltd

Cawachi Ltd maintains a strong liquidity position, with cash and equivalents amounting to ¥38.11 billion, representing 38.1% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, with free cash flow of ¥1.57 billion and a current ratio of 1.54, indicating a solid ability to meet short-term obligations. Profitability metrics show a return on equity (ROE) of 2.76% and a return on assets (ROA) of 1.6%, both below the industry median for drug retailers. The company's gross profit margin is 22.96%, while operating margin is 1.53%, suggesting moderate efficiency in converting revenue to profit. Geographically, Cawachi Ltd is concentrated in Japan, with no disclosed international revenue segments. The company's revenue is primarily derived from its domestic drug retail operations, with no material diversification across product lines or regions. Looking ahead, the company is projected to maintain stable revenue growth, with a year-over-year increase of approximately 1.2% in the current fiscal year. Capital expenditures are expected to remain modest, with a focus on maintaining existing store infrastructure rather than aggressive expansion. Risk factors for Cawachi Ltd are currently low, with no immediate liquidity or dilution concerns identified. The company's debt-to-equity ratio is 0.14, indicating a conservative capital structure. However, the low ROE and ROA suggest potential challenges in generating returns relative to industry peers. Recent filings and transcripts indicate no material changes in the company's strategic direction or financial outlook. The company continues to focus on operational efficiency and customer service in its domestic market.